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TIE haemodynamic effects of adenosine are
thought to result in part from a release of mast
cell amines via A3 receptor stimulation. To inves-
tigate the nature of the receptors involved in
adenosine-induced mast cell degranulation in the
rat isolated omentum we have used adenosine
analogues with varying specificities as activators
of the A1, A2 and A3 receptors, and antagonists
with differing specificities for A1 and A2 recep-
tors. Analogues which act predominantly as A
(e.g. N6-cyclopentyladenosine) or as mixed A/A2
receptor agonists (e.g. adenosine, inosine, 5’-(N-
ethylcarboxamido)adenosine) caused mast cell
degranulation, whereas a predominantly A3 re-
ceptor agonist (IB-MECA) was inactive. Pre-treat-
ment of the omentum with the A/A2 receptor
antagonist 8-phenyltheophylline or with the
more specific A receptor antagonist 8-cyclopen-
tyl-1,3-dipropylxanthine significantly reduced
agonist-induced degranulation. Pre-treatment
with disodium cromoglycate or with BN52021
also reduced degranulation of mast cells in
response to N6-cyclopentyladenosine. In the rat
isolated omental mast cell we conclude that
degranulation is an indirect result of A1 receptor
stimulation. Platelet-activating factor release ap-
pears to mediate at least part of the degranula-
tion.
Key words: Adenosine, Adenosine receptors, N6-
cyclo-pentyladenosinc, 8-cyclopentyl-1,3-dipropylxan-
thine, 5 (N-ethylcarboxamido)adenosinc, IB-MECA,
Inosine, Mast cells, 8-phenyltheophylline, Platelet-
activating factor
Degranulation of rat omental mast
cells by A1 receptor agonists in vitro
A. M. NorthovercA and B. J. Northover
Department of Pharmaceutical Sciences, School of
Applied Sciences, De Montfort University, Leicester
LE1 9BH, UK
CACorresponding Author
Fax: (+44)(0) 116 2577135
Introduction
Adenosine has been shown to increase the
5 release of both histamine and 5-hydroxytryp-
tamine (5HT)
6 from rat isolated mast cells. This
occurs only after such cells have been pre-
stimulated with, for example, an antigen2,3,6 or
the ionophore A23187.1,4,5 Recent evidence
suggests that in antigenically stimulated mast
cells in culture adenosine increases the release
of amines stored in the granules via activation
of adenosine type 3 (A3) receptors7 Some of
the haemodynamic actions of injected adeno-
sine in vivo also have been attributed to the
release of histamine and/or 5HT from mast cells
as a result of activation ofA receptors8-m. The
wide heterogeneity among mast cells located in
11 12 different tissues, however, prompted us to
explore the extent to which an involvement of
A receptors is a general phenomenon.
Various methods may be used to study mast
cell degranulation. Many workers have used rat
(C) 1996 Rapid Science Publishers
isolated peritoneal mast cells,
1-6 but that artifi-
cially precludes interactions occurring between
normally adjacent cell types. Such interactions
12 form an integral part of inflammation. The rat
isolated omentum can be transilluminated and it
contains large numbers of connective tissue
type mast cells located in the so-called milky
spots.3’4 This makes it possible to observe
mast cells in their normal tissue environment,
surrounded by various other cell types. Mast
cells normally stain metachromatically when
they are exposed to toluidine blue,
15 but lose
this property after degranulation.
14 In the pres-
ent work we have investigated the mast cell
degranulating influence of applied adenosine
and some of its synthetic structural analogues in
the rat omentum. The nature of the receptors
that are involved in these responses has been
explored with the aid of selective adenosine
receptor antagonists. We have also investigated
whether or not pre-treatment of the omentum
with disodium cromoglycate (DSCG) can reduce
Mediators of Inflammation Vol 5 1996 341A. M. Northover and B. J. Northover
the degranulating effect of a specific adenosine
type 1 (A1) receptor agonist. In addition, we
have investigated the possibility that adenosine
receptor agonists indirectly degranulate the
mast cells in this preparation by first releasing
platelet-activating factor (PAF) or a cyclo-oxy-
genase product from within the omentum. We
have shown previously that both of these types
of agent occur endogenously and can degqanu-
late mast cells in the rat omentum in vitro.
Methods
Female rats weighing about 250 g were killed
by inhalation of chloroform vapour. The lesser
omentum was removed from the abdomen and
divided into five pieces of approximately equal
size. Each piece was spread out gently on a
microscope slide and flooded with normal
saline (NS) or with NS plus a putative antagon-
ist, and then incubated in a moist atmosphere
at 37C, as described previously.
14 After 5 min
of incubation, the bathing fluid was drained
away and replaced with fresh NS, or with NS
plus agonist, or with NS plus antagonist plus
agonist, or with NS plus antagonist. Incubation
continued for a further 15 min. The specimens
were then drained, washed with distilled water,
and stained for 8min with a solution of
toluidine blue (0.5%) in Mcllvaine’s buffer (pH
4). After rinsing again with distilled water, the
specimens were viewed under a microscope at
100 magnification. The number of metachro-
matically (pink/magenta)-stained mast cells in
each omental milky spot was counted. The
average count for all the milky spots in each
piece of omentum was used to calculate the
mean SEM for each treatment group. Omental
pieces from a minimum of three rats were used
for each treatment group. The number of milky
spots examined varied from 15 to 40 per piece
of omentum.
Compounds tested as possible agonists were
adenosine itself; inosine, which binds weakly to
A1, A2 and A3 receptors;
16 5’-(N-ethylcarbox-
amido) adenosine (NECA), a mixed A1/A2
receptor agonist;16’7 1-deoxy-l-[6-[[(3-iodophe-
nyl)methyl]amino]-9H-purin-9-yl]-N-methyl- [3-D-
ribofuranuronamide (IB-MECA), which is
thought to act predominantly via A3 receptors;e
and N6-cyclopentyladenosine (CPA), which acts
primarily via A receptors.
17 Compounds tested
as putative antagonists were 8-phenyltheophyl-
line (8PT), a mixed A1/A2 receptor antagonist;
18
8-cyclopentyl-l,3 dipropylxanthine (DPCPX),
which is considerably more potent as an A1
receptor antagonist than as an A2 antagonist;9
DSCG, a peritoneal mast cell stabilizer;2’21
BN52021, a PAF-receptor antagonist;
22 and indo-
methacin, a cyclo-oxygenase inhibitor.
Chemicals
Adenosine, inosine, NECA, CPA, 8PT, DPCPX
and DSCG were obtained from Sigma Chemical
Co. Ltd (Poole, UK); IB-MECA from RBI (Natick,
MA, USA); indomethacin from Merck, Sharpe &
Dohme Ltd (Hoddesdon, UK); and toluidine
blue (batch 9244890D) from BDH (Poole, UK).
BN52021 was a gift from Dr P. Braquet, Institut
Henri Beaufor (Le Plessis- Robinson, France).
NECA, CPA, 8PT, DPCPX, IB-MECA and
BN52021 were each initially dissolved in di-
methylsulphoxide, the final concentration of
this solvent to which the omentum was subse-
quently exposed being < 0.5%. Adenosine, in-
osine, DSCG and indomethacin were used as
aqueous solutions, indomethacin being dis-
solved with the aid of a little Na2CO.
Statistics
Bonferroni’s test was used for comparing sev-
24 eral treatment groups with one control group.
Results
Adenosine (1 M), inosine (100 M), NECA
(0.1 xM) and CPA (0.1 M) were each found to
cause significant degranulation of the mast cells
in milky spots of the rat isolated omentum (Fig.
l a,b). Ten-fold lower concentrations of each of
these compounds, however, failed to exert a
significant degranulating effect (Fig. l a,b). Ten-
fold higher concentrations of adenosine (10 txM)
and of NECA (1 xM) were also without a signifi-
cant degranulating effect (Fig. l a,b), whereas a
ten-fold increase in the concentration of CPA
(to 1 btM) caused almost the same amount of
degranulation as the lower concentration of
O. 1 xM (Fig. lb). IB-MECA was ineffective in the
present experiments in a wide concentration
range of O. 1 1O0 bI,M (Fig. 1 a).
Pre-treatment of the omentum with 8PT
(1 lxM) significantly reduced the degranulating
effects of adenosine (1 IxM), inosine (100 btM)
and NECA (0.1 btM) (Fig. l a,b). Pretreatment of
the omentum with DPCPX (0.01 btM) signifi-
cantly reduced the responses to both NECA
(0.1 xM) and CPA (0.1 IM) (Fig. lb). It is
important to note that at these concentrations,
neither 8PT nor DPCPX alone produced a
significant effect on degranulation (mast cell
counts 15.3 -+- 0.8, 17.3 -+- 0.7 respectively). A
ten-fold lower concentration of DPCPX
(0.001 xM) failed to reduce the effect of CPA
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FIG. 1. Effects of various adenosine receptor agonists on
the degranulation of rat omental mast cells, aMast cell
counts are the mean numbers 4- SEM of metachromatically
stained mast cells per omental milky spot. *lower than
control value (p < 0.05, Bonferroni’s test); +higher than the
value for the relevant agonist alone (p < 0.05, Bonferroni’s
test) after treatment with 8PT (1 FM), DPCPX (0.01 #M)
DSCG (100 FM) or BN52021 (10 FM). Abbreviations not used
in the text: BN, BN52021; INDO, indomethacin (1 #M).
significantly (mast cell count 11.9-+-0.8). A ten-.
fold higher concentration of 8PT (10 FM) actu-
ally had a degranulating effect of its own (mast
cell count 12.7 -+- 0.7). A ten-fold higher concen-
tration of DPCPX (0.1 bM) had no greater effect
than 0.01 bM (mast cell count 17.5 -+- 1.6).
Pretreatment of the omentum with DSCG
(100 bM) or with BN52021 (10 bM) significantly
antagonized the effects of added CPA (0.1 bM),
whereas indomethacin (1 bM) was inactive un-
der similar conditions (Fig. lb). DSCG (100 bM)
alone had no significant effect on degranulation
(mast cell count 16.9-+-0.7), BN52021 and
indomethacin alone having been shown pre-
viously to have no degranulating effect at these
concentrations.14
Discussion
The present results show that adenosine, in-
osine, NECA and CPA each degranulate rat
omental mast cells in vitro. Adenosine,
18 in-
osine6 and NECA6’7 have each been reported
to stimulate both the A and A2 types of
receptor, with NECA being more potent than
adenosine in this respect,
17 but with adenosine
in turn being more potent than inosine.6’25 The
degranulating effect of each of these agonists in
the present experiments was counteracted by
pretreating the omentum with 8PT, a mixed A/
A2 receptor antagonist
18 (Fig. l a,b). In contrast,
IB-MECA, which is a much more powerful
activator of A3 receptors than of A or A2
receptors,
6 unexpectedly showed no effect,
even when tested at a concentration of 100
(Fig. l a), suggesting that A3 receptor stimulation
was not involved. This is in marked contrast to
the observation that A3 activation can cause
murine mast cells to degranulate in vivo.9 More-
over, the application of CPA, a relatively specific
A1 receptor agonist,
17 caused a significant de-
gree of mast cell degranulation in the present
experiments (Fig. lb). It is important to note
also that pretreatment with DPCPX, a relatively
specific A1 receptor antagonist,9 significantly
reduced the degranulating effects of both CPA
and NECA (Fig. lb). These results, therefore,
strongly suggest that involvement of A recep-
tors predominated in the present situation. A2
receptor activation, on the other hand, is
unlikely to have been important. A raised level
of cyclic AMP, which one might expect to result
from any A2 receptor stimulation, does not
cause a release of amines from mast cells.2-4
This also accords with the fact that any A2-
stimulating action of NECA which might have
been unmasked after blocking its A receptor-
mediated effect with DPCPX, actually produced
no observable effect on degranulation in the
present experiments (Fig. lb). It is worth noting
here that other workers have found that 10
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adenosine was less active than 1 bM adenosine
in reducing vascular luminal diameter, which is
another phenomenon thought to be due to
mast cell degranulation.25 The affinity constants
at adenosine-sensitive binding sites shown by
both adenosine and NECA are higher at A2 than
at A1 receptors.
18 The lesser degranulating
effect of the higher concentrations (10 bM and
1 M respectively) of these two compounds
may have been due to partial mast cell stabiliza-
tion exerted via a stimulation of A2 (adenylate
cyclase stimulating) receptors that appeared
only at these higher concentrations. The de-
granulating effects exerted via A1 (adenylate
cyclase inhibitory) receptors, on the other
hand, may already have become maximal at the
lower concentration tested (1 bM and 0.1
respectively). A similarity in the degranulating
effect shown by CPA at 0.1 bM and 1 bM (Fig.
lb) would thus be consistent with its very weak
A2 receptor agonist activity.
17
Those AI receptors which seem to be respon-
sible for the present observations may reside in
the mast cell membranes or they may be
located in other cells within the omentum.
Activation of the A1 receptors in various types
of cell can lead to either an increase or a
decrease in the coupling of surface receptors to
their G proteins.
26 Hence, mast cell degranula-
tion that was observed here may have been
produced indirectly, rather than as a direct
result of adenosine receptor stimulation of the
mast cell itself. Other workers have put forward
a similar proposition. In support of this
hypothesis, it was found that pretreatment of
the omentum with BN52021, a PAF-receptor
antagonist,
22 significantly reduced the degranu-
lating effects of added CPA, although indometh-
acin, a cyclo-oxygenase inhibitor,23 did not (Fig.
lb). Under the present experimental conditions,
therefore, a release of PAF may mediate part of
the degranulation that was seen. This would
correlate well with our earlier observation using
this preparation, that PAE and possibly thromb-
oxane A2, appeared to be involved as mediators
of the mast cell degranulation that was induced
by the NO-synthase inhibitor N-nitro-L-arginine
methyl ester.14 However, in addition to hista-
mine, 5-hydroxytryptamine and PAE various
pro-inflammatory cytokines are known to be
released from stimulated mast cells.11’12 We
have no evidence to implicate or rule out an
involvement of cytokines or other such sub-
stances here. It is possible that protection
against the degranulating effect of CPA that was
shown by DSCG (Fig. lb) may have resulted
from reduced release of one of these other
substances,27 but equally it may have been due
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to an adenosine receptor blockin
action of the
type described by earlier workers. *
Finally, it must be noted that mast cells vary
considerably in their responsiveness to stimula-
tion by different agents.I1’12 Onecannot extra-
polate with any degree of certainty, therefore,
between different organs or species. Mast cells
in the rat omentum may turn out to be
exceptional. They certainly differ from those in
rat skin29 in being refractory to degranulation
with a potent A3 receptor-specific agonist such
as IB-MECA, but in being sensitive to a potent
Al-receptor selective agonist such as CPA.
Further work is needed to explore the
pharmacological responsiveness of mast cells
located in different rat tissues.
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